Hanx Biopharmaceuticals

Hanx Biopharmaceuticals is an innovation-driven biotechnology company headquartered in Wuhan, China. It focuses on the discovery and development of first-in-class and best-in-class therapies primarily targeting cancer and autoimmune diseases through next-generation immunotherapies—especially bispecific antibodies that modulate multiple immune pathways simultaneously. Its lead programs include the CTLA‑4/SIRPα bispecific candidate HX044 now entering early clinical trials for advanced solid tumors resistant to current checkpoint inhibitors; the dual PD‑1/CD47-targeting bispecific candidate HX009 advancing through global phase II studies for lymphoma/melanoma/biliary tract cancer; a multi-target kinase inhibitor narazaciclib co-developed with Traws Pharma now being tested against glioblastoma; plus several preclinical assets focused on novel targets like OX40 or VEGF/PD-L axis. The firm leverages cross-border expertise between China/U.S., has established key partnerships to support its R&D pipeline—including licensing out commercial rights to some products—and is preparing an IPO to fund further clinical expansion globally. Its mission centers around providing affordable innovative therapies addressing major unmet needs worldwide by combining structural biology insights with translational medicine approaches.